A step forward
in treating RA
A first-of-its-kind lab test to guide targeted treatment decisions in rheumatoid arthritis
PrismRA®, a molecular signature test, brings precision medicine to RA treatment, providing insights that guide therapy selection and give patients their best opportunity to reach treatment goals. PrismRA identifies RA patients unlikely to respond to tumor necrosis factor-α inhibitor (TNFi) therapies.
No more waiting to see if a therapy
is suited to a patient
By leveraging the early therapeutic window, when intervention is most effective, PrismRA can help prevent the cost associated with delayed effective treatment.
Improves patient response rate by up to 38% by accurately stratifying patients prior to starting or changing therapy1-4
Enable providers to consider alternative approved therapies in patients unlikely to adequately respond to TNF inhibitor therapies.
Save time, a patient’s most valuable and limited resource, by directing them to a more appropriate therapy sooner.
Actionable results to
help RA patients reach treatment targets
PrismRA gives providers insights to help give patients their best opportunity to reach treatment goals and avoid a class of therapies unlikely to deliver an adequate response.1,3,4
Clinical utility
Test predicts likelihood of not achieving response, low disease activity, or remission across multiple clinical metrics at 3 and 6 months, including ACR50, ACR70, DAS28-CRP, and CDAI with statistical significance1,3,4
Multiple Studies
The PrismRA molecular signature test was studied in biologic-naïve and biologic-exposed patients (N=730 patient samples) who had moderate-to-severe RA.1,3-5
